Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)
BehavioralCBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID).
NCT Number: NCT06463470
CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID). The purpose of this evaluation is to determine the feasibility, acceptability and effectiveness of this treatment.
It is hypothesised that this treatment will be feasible and acceptable to clinicians, carers and patients and will be effective in reducing symptoms of ARFID for patients.
Looking for future studies?
Notify Me12 year–25 year
All sexes
Interventional
Not applicable
Orygen Youth Health - Parkville - Parkville, Melbourne, Victoria, Australia
CBT-AR describes an adaption of cognitive behavioural therapy that is appropriate for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID). This therapy will be delivered by trained clinicians (e.g. psychologists, mental health nurses) and involves weekly sessions for 18-30 sessions (up to 30 sessions for underweight patients). This therapy will be delivered face-to-face whenever possible. If required (participant not able to travel for a session etc.) online or telephone sessions will be conducted.
This therapy involves four stages as described below.
Clinicians will collect data on adherence weekly. A measure of patient, parent/guardian and clinician satisfaction will be collected at the end of stage 4.
Parents/guardians of individuals <16yrs, or parents/guardians of patients who are underweight and living at home irrespective of age are involved in therapy through attending psychoeducation sessions and supporting the completion of homework.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CBT-AR describes an adaption of cognitive behavioural therapy for use with individuals diagnosed with Avoidant/Restrictive Food Intake Disorder (ARFID).
Time frame: Upon conclusion of the study (week 18-30)
Feasibility will be determined based on whether patients attended sessions. This information will be collected weekly.
Clinicians will also record if a patient drops out of therapy and why (if known)
Time frame: The CTS will be completed upon conclusion of the study (week 18-30)
This outcome will be measured using 'The Compliance to Treatment Schedule' (CTS).
Time frame: The CSQ will be completed upon conclusion of the study (week 18-30)
This outcome will be measured using the 'Client Satisfaction Questionnaire' (CSQ). Scores range from 8-32, with higher scores indicative of greater satisfaction.
Time frame: Adverse events will be collected weekly between baseline and the conclusion of the study (week 18-30)
This outcome will be measured using recordings of adverse events. Adverse events will be monitored weekly. Participants will be asked open-ended questions to determine whether they have experienced an adverse event in the past week. If an adverse event is elicited, in addition to describing the event and associated treatments, clinicians will ask questions to determine the severity and seriousness of the event, the likelihood that it is related to CBT-AR, and the outcome of the event. Examples of possible events might include vomiting or an allergic reaction to food in session or heightened anxiety around eating between sessions.
Time frame: Qualitative feedback will be collected at the conclusion of the study (end of stage 4, week 20-30)
This outcome will be measured using recordings of qualitative feedback. Qualitatively, clinicians are given an open text box and invited to enter any comments they might have including comments relating to the acceptability of the treatment.
Time frame: The PARDI-AR-Q will be assessed at baseline, and at the conclusion of stages 2 (week 4-6) and 3 (week 18-28) and at conclusion of the study (week 18-30)
This outcome will be measured using the Pica, ARFID, and Rumination Disorder Interview - ARFID Questionnaire (PARDI-AR-Q). Scores range from 0-6 for each subscale of severity of impact, sensory based avoidance, lack of interest, and concern about aversive consequences, with higher scores indicating greater severity.
Time frame: The FNS will be assessed at baseline and weekly and upon conclusion of the study (week 18-30)
This outcome will be measured using the Food Neophobia Scale (FNS). Scores range from 0-42 on the shortened FNS, with higher scores indicative of greater food neophobia.
Time frame: BMI will be assessed at baseline and weekly and upon conclusion of the study (week 18-30)
Calculated using weight and height Weight will be measured using digital scales and height measured using stadiometer
Time frame: The DASS-Y will be assessed at baseline and at the conclusion of stages 2 and 3 and at conclusion of the study (week 18-30)
Depression, Anxiety, Stress Scale for Youth (DASS-Y). Scores range from 0-42 on each subscale of depression, anxiety and stress, with higher scores indicating greater severity.
Time frame: The ReQol will be assessed at baseline and at the conclusion of stages 2 and 3 and at conclusion of the study (week 18-30)
Recovering Quality of Life Questionnaire (ReQol). Scores range from 0-40 with higher scores indicating higher quality of life.
Time frame: This will be measured upon conclusion of the study (week 18-30)
Working Alliance Inventory - Short Revised (WAI-SR). Scores range from 4-20 on each of the subscales of agreement of tasks, goals and bond, with higher scores indicative of stronger therapeutic alliance.
Orygen
Other
Cognitive Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR): An Evaluation of the Feasibility, Acceptability and Effectiveness in Individuals Aged 12 to 25 Years
Acronym: CBT-AR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05954728
Avoidant Restrictive Food Intake Disorder, Avoidant/Restrictive Food Intake Disorder (ARFID)
Boston, Massachusetts, United States
View Trial DetailsNCT02963220
Avoidant Restrictive Food Intake Disorder, Avoidant/Restrictive Food Intake Disorder (ARFID)
Boston, Massachusetts, United States
View Trial DetailsNCT06898177
Avoidant Restrictive Food Intake Disorder, Avoidant/Restrictive Food Intake Disorder (ARFID)
Boston, Massachusetts, United States
View Trial DetailsNCT07641205
Avoidant Restrictive Food Intake Disorder, Avoidant/Restrictive Food Intake Disorder (ARFID)
Boston, Massachusetts, United States
View Trial Details